Bloomberg Talks: Christian Sewing & Roland Busch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
RC365 Holding Reports Full Year 2025 Earnings
RC365 Holding (LON:RCGH) Full Year 2025 Results Key Financial Results Revenue: HK$14.1m (down 36% from FY 2024). Net loss: HK$30.8m (loss narrowed by 17% from FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period RC365 Holding's share price is broadly unchanged from a week ago. Risk Analysis Be aware that RC365 Holding is showing 4 warning signs in our investment analysis and 2 of those are significant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
9 minutes ago
- Yahoo
Rentokil Initial plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Rentokil Initial plc (LON:RTO) shareholders are probably feeling a little disappointed, since its shares fell 2.5% to UK£3.62 in the week after its latest half-yearly results. Revenues were in line with forecasts, at UK£2.7b, although statutory earnings per share came in 18% below what the analysts expected, at UK£0.056 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Following the recent earnings report, the consensus from twelve analysts covering Rentokil Initial is for revenues of UK£5.36b in 2025. This implies a measurable 3.1% decline in revenue compared to the last 12 months. Per-share earnings are expected to surge 28% to UK£0.12. In the lead-up to this report, the analysts had been modelling revenues of UK£5.37b and earnings per share (EPS) of UK£0.14 in 2025. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a real cut to EPS estimates. Check out our latest analysis for Rentokil Initial It might be a surprise to learn that the consensus price target was broadly unchanged at UK£4.23, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Rentokil Initial at UK£5.50 per share, while the most bearish prices it at UK£3.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 6.1% by the end of 2025. This indicates a significant reduction from annual growth of 19% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 3.5% per year. It's pretty clear that Rentokil Initial's revenues are expected to perform substantially worse than the wider industry. The Bottom Line The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Rentokil Initial going out to 2027, and you can see them free on our platform here.. Plus, you should also learn about the 4 warning signs we've spotted with Rentokil Initial (including 1 which shouldn't be ignored) . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
Chapel Down Group's (LON:CDGP) investors will be pleased with their notable 46% return over the last three years
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. For example, the Chapel Down Group Plc (LON:CDGP) share price is up 46% in the last three years, clearly besting the market return of around 35% (not including dividends). With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the three years of share price growth, Chapel Down Group actually saw its earnings per share (EPS) drop 60% per year. This means it's unlikely the market is judging the company based on earnings growth. Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics. We severely doubt anyone is particularly impressed with the modest 1.4% three-year revenue growth rate. While we don't have an obvious theory to explain the share price rise, a closer look at the data might be enlightening. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time. A Different Perspective While the broader market gained around 18% in the last year, Chapel Down Group shareholders lost 43%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for Chapel Down Group you should be aware of, and 1 of them is a bit concerning. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
